US Stock MarketDetailed Quotes

IART Integra Lifesciences

Watchlist
  • 21.800
  • +0.090+0.41%
Close Dec 20 16:00 ET
  • 21.800
  • 0.0000.00%
Post 16:54 ET
1.68BMarket Cap-242.22P/E (TTM)

Integra Lifesciences Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Integra Lifesciences Q3 2024 Earnings Date

Currency：USDNov 4, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
375.79M
380.83M
+5.05M
Beat Est.
-1.73%
-0.41%
+1.34%
EPS
-0.08
-0.14
-0.06
Miss Est.
-134.33%
-158.33%
-69.90%
Analyst Rating
Underperform

Dec 21, 2024

Integra Lifesciences Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 411.712M--
--2024/Q4-- / 445.154M--
Nov 4, 20242024/Q3380.834M / 375.787M--
Jul 29, 20242024/Q2418.175M / 413.118M--
May 6, 20242024/Q1368.872M / 361.961M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 411.712M--
--2024/Q4-- / 445.154M--
Nov 4, 20242024/Q3380.834M / 375.787M--
Jul 29, 20242024/Q2418.175M / 413.118M--
May 6, 20242024/Q1368.872M / 361.961M--

Unlock Free Earnings Estimates

Integra Lifesciences Earnings Reports

  • Integra Lifesciences | 10-Q: Q3 2024 Earnings Report

    Nov 4 16:16 ET

  • Integra Lifesciences | 8-K: Integra LifeSciences Reports Third Quarter 2024 Financial Results

    Nov 4 06:24 ET

  • Integra Lifesciences | 10-Q: Q2 2024 Earnings Report

    Jul 29 16:12 ET

  • Integra Lifesciences | 8-K: Integra LifeSciences Reports Second Quarter 2024 Financial Results

    Jul 29 06:19 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 21, 2024

    Underper form

    • Buy

      16.67%

    • Hold

      33.33%

    • Sell

      50.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data

    Investment Theme Brain-Computer Interface
    Brain-Computer Interface
    Intraday+0.39%